Cavazzoni earned her medical degree from McGill University and subsequently was a fellow at the University of Ottawa.[2] She then joined the University of Ottawa as an assistant professor before moving to the pharmaceutical industry,[3] where she worked at Pfizer.[4]
She moved to the U.S. Food and Drug Administration in 2018, and was named acting director of the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research in 2020[5][6] and director in 2021.[4] During the COVID-19 pandemic, Cavazzoni has spoken publicly about the need for science to guide policies[7] and about the future of the Center for Drug Evaluation and Research after the COVID-19 pandemic.[8] She also noted that she would hand Donald Trump a blank sheet of paper if asked to submit a list of workers who should not receive due process protections.[9]
Research
While she worked at the Royal Ottawa Hospital, Cavazzoni examined the link between genetics and personality, and the chemicals implicated in brain chemistry.[10] She further examined the connections between diabetes and patients receiving antipsychotic medications.[11]
^Florko, Nicholas (June 23, 2020). "The new Janet: The FDA turns to a quiet problem-solver who brings expertise - and a little controversy". STAT; Boston – via ProQuest.
^Florko, Nicholas (May 22, 2020). "FDA shuffles longtime division head, Janet Woodcock, to focus exclusively on Covid-19 vaccine project". STAT; Boston – via ProQuest.
^Sibbald, Barbara (30 May 1999). "Busting the happiness barrier: Scientists are searching for common ground to make us happier". The Ottawa Citizen. pp. C3 – via ProQuest.
